公开(公告)号：US20230313225A1

公开(公告)日：2023-10-05

申请号：US18011742

申请日：2021-11-08

申请人： CANSINO BIOLOGICS INC.

发明人： Meng XIAO ,  Yunjie LIU ,  Tao ZHU ,  Yunli XU ,  Can XU ,  Junqiang LI ,  Shoubai CHAO

IPC分类号： C12N15/86 ,  C12M1/00 ,  A61K39/215

CPC分类号： C12N15/86 ,  C12M29/10 ,  A61K39/215 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2710/10362 ,  C12N2500/32 ,  A61K2039/5256

摘要： Provided is a method for preparing an adenovirus vector vaccine by means of a perfusion culture process. The method comprises a step of culturing adenovirus host cells, and in particular a step of adjusting the perfusion rate by means of at least two stages according to cell density. The method increases the single cell yield of a virus after infection and the specific activity of a virus harvest liquid while achieving high-density growth of adenovirus host cells.

公开(公告)号：US20200255862A1

公开(公告)日：2020-08-13

申请号：US16806013

申请日：2020-03-02

申请人： CANSINO BIOLOGICS INC.

发明人： Tao ZHU ,  Haiyan CUI ,  Weiwei CHEN ,  Lei DUAN ,  Junqiang LI ,  Jin MA ,  Chunlin XIN ,  Zhongqi SHAO ,  Xuefeng YU ,  Huihua MAO

IPC分类号： C12N15/86 ,  A61K39/235

摘要： Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.

公开(公告)号：US20230183298A1

公开(公告)日：2023-06-15

申请号：US18150496

申请日：2023-01-05

申请人： CANSINO BIOLOGICS INC.

发明人： Haomeng WANG ,  Zhihong YAN ,  Qiaoling YAN ,  Juan SHAO ,  Jianming SHI ,  Xiuwen SUI ,  Junqiang LI ,  Tao ZHU

IPC分类号： C07K14/22 ,  A61K39/116

CPC分类号： C07K14/22 ,  A61K39/116

摘要： Provided are a protein antigen subjected to site-directed mutation and site-directed modification, and a method for site-directed mutation and site-directed modification of the protein antigen. The method comprises: site-directedly introducing an unnatural amino acid into a specific site of the protein antigen by genetic codon expansion technique; and performing site-directed modification with the protein antigen by the unnatural amino acid and a modifier, wherein the modifier is a receptor agonist such as tripalmitoyl-S-glyceryl cysteine and monophosphoryl lipid A. Further provided is use of the protein antigen subjected to site-directed mutation and site-directed modification, such as use as a vaccine.

公开(公告)号：US20230173058A1

公开(公告)日：2023-06-08

申请号：US17922328

申请日：2021-04-01

申请人： CANSINO BIOLOGICS INC. ,  ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

发明人： Junqiang LI ,  Weixue SI ,  Tao ZHU ,  Yunli XU ,  Jie DENG ,  Shoubai CHAO

IPC分类号： A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14

CPC分类号： A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14 ,  A61K2039/5256

摘要： Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.

公开(公告)号：US20220088186A1

公开(公告)日：2022-03-24

申请号：US17420608

申请日：2020-01-07

申请人： CANSINO BIOLOGICS INC .

发明人： Tao ZHU ,  Junqiang LI ,  Shoubai CHAO ,  Chunlin XIN ,  Wei MIAO ,  Xishan LU

IPC分类号： A61K39/25 ,  A61K39/15 ,  A61K39/12 ,  A61K39/39 ,  A61K39/00 ,  A61P31/22

摘要： Disclosed is an SamRNA vaccine, including a recombinant viral vector which includes: i) a viral gene replication complex including nucleotide sequences encoding viral gene replication-related proteins nsP1, nsP2, nsP3, and nsP4; and ii) a nucleotide sequence encoding at least one antigen. According to the SamRNA vaccine of the present invention, in addition to that a promoter of a modified adenoviral vector itself can transcribe an antigen gene to form mRNA, the viral gene replication-related proteins nsP1-4 use RNA as a template to synthesize a large amount of mRNAs, and the immune effect of a target antigen is greatly improved.

公开(公告)号：US20180214541A1

公开(公告)日：2018-08-02

申请号：US15940871

申请日：2018-03-29

申请人： CANSINO BIOLOGICS INC.

发明人： Junqiang LI ,  Danqing MIAO ,  Mingming YANG ,  Zhongqi SHAO ,  Tao ZHU ,  Xuefeng YU

IPC分类号： A61K39/385 ,  A61K39/102 ,  A61K47/64

摘要： Provided are a fusion protein and a construction method thereof. The fusion method consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.